






A**B****C****D****E**

Supplemental Figure S2. Screening of venetoclax combinations and respective single agents against non-leukemic human stromal and bone marrow mononuclear cells.

Venetoclax-inclusive combinations and their respective single agents were tested across a 7-concentration series ranging 10 μ M to 10 nM (the identical range tested in ex vivo screening of patient samples) for potential efficacy against non-leukemic HS-5 stromal cells **(A)**, HS-27 stromal cells **(B)**, and healthy mononuclear cells (MNCs) **(C)**. HS-5 and HS-27 cells were tested in three independent experiments performed in triplicate; bone marrow mononuclear cells from three different healthy individuals were tested in triplicate. Mean AUC values (as a percent of the maximum possible value for the dose range tested) are ranked for each treatment for single agents and combinations. Error bars represent standard deviation. **(D)** Comparison of average AUC values from the three tested healthy donor MNC samples with the median AUC for each combination across primary AML MNC samples. Points to the right of the diagonal line indicate greater overall sensitivity in AML samples relative to healthy MNCs. **(E)** Bar plot for AML patient sample 22-00043 comparing matched ex vivo sensitivity (AUC %) for a select panel of inhibitors tested on the respective MNC (blue) and stromal (green) compartments.